Experience with 5% ethanolamine oleate for sclerotherapy of oral vascular anomalies: a cohort of 15 consecutive patients

Página do item simplificado
dc.creatorCamila de Nazaré Alves de Oliveira Kato
dc.creatorMichel Campos Ribeiro
dc.creatorMárcio Bruno Figueiredo do Amaral
dc.creatorSoraya de Mattos Camargo Grossmann Almeida
dc.creatorMaria Cássia Ferreira de Aguiar
dc.creatorRicardo Alves de Mesquita
dc.date.accessioned2024-10-25T22:54:05Z
dc.date.accessioned2025-09-08T23:02:50Z
dc.date.available2024-10-25T22:54:05Z
dc.date.issued2019-01
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1016/j.jcms.2018.11.009
dc.identifier.issn1878-4119
dc.identifier.urihttps://hdl.handle.net/1843/77668
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofJournal of Cranio-Maxillofacial Surgery
dc.rightsAcesso Restrito
dc.subjectEthanolamine
dc.subjectSclerotherapy
dc.subjectVaricose veins
dc.subjectVascular malformations
dc.subjectLip
dc.subjectGuidelines as topic
dc.subjectPain
dc.subjectPatient satisfaction
dc.subject.otherEthanolamine
dc.subject.otherSclerotherapy
dc.subject.otherVaricose vein
dc.subject.otherVascular malformation
dc.titleExperience with 5% ethanolamine oleate for sclerotherapy of oral vascular anomalies: a cohort of 15 consecutive patients
dc.typeArtigo de periódico
local.citation.epage111
local.citation.issue1
local.citation.spage106
local.citation.volume47
local.description.resumoPurpose To describe the effectiveness and safety of a sclerotherapy protocol with 5% ethanolamine oleate (EO) at 0.1 mL/3 mm for oral vascular anomalies (OVAs). Our hypothesis is that EO applied at a concentration of 5% may decrease the number of sessions necessary for clinical healing. Materials and methods We describe a cohort of 15 consecutive patients. OVAs <20 mm were included. Clinical data of the OVAs were collected. Descriptive and bivariate statistical analyses were performed. Results Fifteen of the 19 OVAs were varicosities and the lower lip was the most affected site (n = 7). The median size was 6 mm, and one session was required in 89.5% of cases for clinical healing within 28 days. The pain/burning score was low (<2) for most lesions (63.1%) and the degree of satisfaction was high (>8) for all OVAs. The number of applications, final volume of drug and time to resolution differed significantly according to the size of the anomaly. Conclusion The protocol with 5% EO was shown to be effective and safe to treat OVAs <20 mm, and with a decrease in the number of sessions, volume and time to resolution, without complications and with high patient satisfaction.
local.identifier.orcidhttps://orcid.org/0000-0001-5134-3466
local.identifier.orcidhttps://orcid.org/0000-0003-3207-4007
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE CLÍNICA
local.publisher.initialsUFMG
local.url.externahttps://www.sciencedirect.com/science/article/pii/S1010518218305079

Arquivos

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG